Inex Pharmaceuticals has signed an exclusive research collaboration agreement with Alnylam Pharmaceuticals to evaluate use of Alnylam’s RNAi therapeutics with Inex’s systemic liposomal delivery technology. The collaboration will evaluate multiple targets including apolipoprotein B (apoB), a protein involved in cholesterol metabolism. The agreement will build on preliminary data published by Alnylam and Nature magazine, showing that the systemic delivery of an apoB RNAi therapeutic si...